Cellarity
Sarah (Chi Hua) Lin is a highly accomplished scientist with extensive experience in the hematology space and a strong background in assay development. Currently serving as a Principal Scientist at Cellarity since January 2021, Sarah has successfully led the development of cell-based assays for high throughput screening and target engagement assays. Previous roles include Senior Staff Scientist at New York Blood Center, where Sarah played a key role in a study on UM171-Expanded CB in patients with high risk leukemia and myelodysplasia. Sarah's academic credentials include a Ph.D. in Physiology from New York Medical College and a Master of Science in Biotechnology and Laboratory Science from National Yang Ming University, complemented by early research experience at Stony Brook University and China Medical University.
Cellarity
1 followers
Founded by Flagship Pioneering, Cellarity is the first company developing medicines through an understanding of cell behaviors. The company’s broad platform harnesses single-cell technologies and machine learning to digitize and quantify cellular behaviors, unravel the network dynamics that govern those behaviors, and generate medicines that can direct them.